Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMSC01 in Severe and Critical COVID-19
NCT05501418Phase 2Active, not recruiting
- Sponsor
- Ever Supreme Bio-Technology
- Start
- Aug 2020
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of human umbilical cord derived mesenchymal stem cells in coronavirus disease 2019 (COVID-19), sponsored by Ever Supreme Bio-Technology. Started Aug 2020; status: active, not recruiting.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05501418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501418.